Such analogs have been proposed for prostate cancer theragnostics, either alone or in combination with other modalities directed to alternative and/or complementary biomolecular targets, such as, for example, radiolabeled inhibitors of prostate-specific membrane antigen (PSMA) on cancer cells [33,34]. The gene discussed is FOLH1; the disease is cancer.